Bayer's Legal and Financial Tightrope: A Week of Critical Tests

Bayer shares surge 95% as a new stroke drug shows promise, but a Supreme Court case on glyphosate and rising debt pose major threats to its recovery.

Bayer shares, trading at EUR 41.10, have nearly doubled over the past year, posting a staggering 95% gain. Yet the coming days present a series of events that could redefine the company's trajectory, pitting promising clinical data against deep-seated legal and financial challenges.

The immediate catalyst is a breakthrough in the company's pharmaceutical pipeline. Detailed results from the Phase III OCEANIC-STROKE study, published in the New England Journal of Medicine, show the investigational drug Asundexian reduced ischemic strokes by 26% compared to a placebo. Critically, the data from over 12,000 participants confirmed no increased risk of major bleeding. The U.S. FDA has already granted the drug Fast-Track designation, though it remains unapproved globally. This success is strategically vital for Bayer as it seeks to offset impending revenue declines. Patents for its blockbuster drugs Xarelto and Eylea are set to expire this year.

A Shareholder Agenda and Mounting Debt

The corporate calendar is packed. On Monday, the company will release the prepared remarks of CEO Bill Anderson and Supervisory Board Chairman Norbert Winkeljohann, with markets keen for specifics on a new organizational model. This also marks the start of a quiet period ahead of the quarterly report due on May 12th.

Friday brings the virtual Annual General Meeting. The board has proposed a reduced dividend of EUR 0.11 per share, with payment to follow shortly after shareholder approval. The meeting will also include the planned election of Alfred Stern and Marcel Smits to the Supervisory Board.

Financially, the picture is mixed. Bayer reduced its net financial debt by approximately 8% to just under EUR 30 billion by the end of last year. However, management anticipates it will rise again in the current year, potentially reaching EUR 33 billion. This forecast is tied directly to ongoing legal battles in the United States.

The Supreme Court Gambit and a Broken Bottom Line

The most consequential event occurs on April 27th, when the U.S. Supreme Court begins oral arguments in a pivotal glyphosate case. The core legal question—whether federal law preempts state-level liability claims against Bayer—could redefine the company's long-term litigation risk in North America. Roughly 65,000 pending claims hinge on the outcome, alongside a massive class settlement awaiting final approval worth $7.25 billion. DZ Bank analyst Peter Spengler views a favorable ruling as key to making legal risks more calculable, forming the basis for his more positive stance on the stock.

The financial toll of these disputes is already severe. The company posted a net loss of EUR 3.6 billion last year, driven largely by provisions for litigation. Revenue for 2025 was EUR 45.6 billion, with EBITDA falling to EUR 9.7 billion. Free cash flow contracted by almost one-third, pressured further by the patent cliff for the blood thinner Xarelto.

Analyst opinions reflect this tension. Deutsche Bank Research raised its price target to EUR 43 but maintains a "Hold" rating. In contrast, UBS reaffirmed a "Buy" recommendation with a EUR 52 target; analyst Matthew Weston points specifically to the growth dynamics of newer pharma products Nubeqa and Kerendia. The stock currently sits about 16% below its 52-week high of EUR 49.17.

Looking ahead, Bayer targets EBITDA between EUR 9.6 and 10.1 billion for 2026 and expects a return to mid-single-digit sales growth from 2027. The upcoming first-quarter report will be scrutinized for signs that cost-cutting measures are taking hold and that the agricultural business remains supportive. For now, investors face a week where clinical promise and legal peril are on a direct collision course.